This compound is a key pharmaceutical intermediate for the synthesis of Benazepril, an angiotensin-converting enzyme (ACE) inhibitor widely used to treat hypertension and heart failure. As a critical chiral building block, it provides the 3S-amino-benzazepinone core structure essential for Benazepril’s pharmacological activity. Its tartrate salt form enhances stability and crystallinity, facilitating purification and handling in GMP-compliant manufacturing processes. Beyond Benazepril production, it serves as a reference standard in analytical laboratories for quality control of ACE inhibitor drugs. It is also utilized in synthetic chemistry research for developing novel benzazepine-based cardiovascular agents and studying structure-activity relationships (SAR) of renin-angiotensin system modulators.

GHS Classification: Not formally classified (low hazard) Hazard Statements: None assigned This pharmaceutical intermediate has low acute toxicity (no LD50 data available, but considered non-toxic under normal handling). Direct skin contact may cause mild transient irritation; eye contact could lead to slight redness or discomfort. Inhalation of dust may irritate the respiratory tract, causing minor coughing or throat dryness. No evidence of carcinogenicity, mutagenicity, or reproductive toxicity has been reported in long-term studies. As a precaution, avoid ingestion and prolonged skin exposure. Handle in a fume hood with nitrile gloves, safety goggles, and an N95 respirator. In case of eye contact, rinse thoroughly with water for 15 minutes. Store separately from oxidizing agents and strong acids. Dispose of waste per local hazardous waste regulations.